|
|
Volumn 30, Issue 11, 2012, Pages 1015-1016
|
|
Calamitous HCV trial casts shadow over nucleoside drugs.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIVIRUS AGENT;
BMS-790052;
DACLATASVIR;
DNA DIRECTED RNA POLYMERASE;
IMIDAZOLE DERIVATIVE;
NUCLEOSIDE;
CHEMICALLY INDUCED DISORDER;
DRUG ANTAGONISM;
DRUG COMBINATION;
HEART DISEASE;
HUMAN;
KIDNEY DISEASE;
NOTE;
PATIENT SELECTION;
PHASE 2 CLINICAL TRIAL (TOPIC);
ANTIVIRAL AGENTS;
CLINICAL TRIALS, PHASE II AS TOPIC;
DNA-DIRECTED RNA POLYMERASES;
DRUG THERAPY, COMBINATION;
HEART DISEASES;
HUMANS;
IMIDAZOLES;
KIDNEY DISEASES;
NUCLEOSIDES;
PATIENT SELECTION;
|
|
EID: 84874567377
PISSN: None
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt1112-1015 Document Type: Note |
|
Times cited : (11)
|
|
References (0)
|
